Groupama Asset Managment Grows Holdings in Denali Therapeutics Inc. $DNLI

Key Points

• Groupama Asset Management increased its stake in Denali Therapeutics by 31.1%, bringing its total shares to 144,488 valued at approximately $2.14 million.
• Denali Therapeutics reported an EPS of ($0.72) for the last quarter, outperforming analyst expectations of ($0.74).
• Hedge funds and institutional investors collectively own 92.92% of Denali Therapeutics' stock, indicating significant institutional interest.

Groupama Asset Managment grew its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 31.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 144,488 shares of the company's stock after purchasing an additional 34,281 shares during the quarter. Groupama Asset Managment owned about 0.10% of Denali Therapeutics worth $2,136,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in DNLI. SG Americas Securities LLC raised its stake in shares of Denali Therapeutics by 339.6% in the 1st quarter. SG Americas Securities LLC now owns 48,365 shares of the company's stock valued at $658,000 after purchasing an additional 37,362 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Denali Therapeutics by 4.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 85,075 shares of the company's stock valued at $1,733,000 after acquiring an additional 3,411 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Denali Therapeutics in the 1st quarter valued at about $254,000. GAMMA Investing LLC grew its holdings in shares of Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock valued at $108,000 after acquiring an additional 5,705 shares in the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of Denali Therapeutics by 260.9% in the 4th quarter. First Trust Advisors LP now owns 65,442 shares of the company's stock valued at $1,334,000 after acquiring an additional 47,308 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Robert W. Baird reduced their price target on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Wedbush reduced their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Morgan Stanley reduced their price target on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating for the company in a report on Monday, August 18th. Finally, Bank of America reduced their price target on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $33.62.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI traded up $0.13 during trading on Monday, hitting $15.62. 551,566 shares of the company were exchanged, compared to its average volume of 1,415,302. The business's 50 day moving average is $14.31 and its 200-day moving average is $14.97. The company has a market capitalization of $2.28 billion, a P/E ratio of -5.60 and a beta of 1.36. The company has a quick ratio of 10.27, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same period last year, the company earned ($0.59) earnings per share. Equities analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Activity at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 495,282 shares of the firm's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the sale, the chief executive officer directly owned 253,071 shares in the company, valued at $3,796,065. This trade represents a 66.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Carole Ho sold 2,937 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider owned 217,391 shares of the company's stock, valued at approximately $2,952,169.78. This represents a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 501,962 shares of company stock worth $7,520,799 over the last three months. Company insiders own 12.50% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.